FINEVISION HP Trifocal IOLs
Beaver-Visitec International, Inc. · Decision date Sep 10, 2025
What did the FDA approve?
FDA records P240038 as an original PMA application. The recorded decision is approval, dated Sep 10, 2025.
FDA approval order statement
Approval for the FINEVISION HP Trifocal Intraocular Lens (IOL). The FlNEVISION HP Trifocal intraocular Lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed by phacoemulsification. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity compared to a monofocal IOL.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 10, 2025
Regulatory record facts
- Identifier
- P240038
- Regulatory pathway
- Premarket approval application
- Applicant
- Beaver-Visitec International, Inc.
- Product code
- HQL
- Decision code
- APPR
- Decision date
- Sep 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Beaver-Visitec International, Inc.
- Product code
- HQL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240038 received
Application receipt date recorded by FDA.
P240038 · FDA decision
APPR
P240038/S003 · Related supplement
FINEVISION HP Trifocal IOLs
P240038/S004 · Related supplement
FINEVISION HP Trifocal IOLs
Timeline entries are records held by MedtechLedger for P240038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S003 | Beaver-Visitec International, Inc. | PMA supplement | Sep 25, 2026 | FDA |
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Beaver-Visitec International, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 500 Totten Pond Rd., Waltham, MA, 02451
Sources and methodology
- Original FDA record: P240038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




